Type 2 Diabetes

In the phase 3a REIMAGINE 1 trial, once-weekly cagrilintide–semaglutide reduced HbA1c vs placebo at 40 weeks in adults with early-stage type 2 diabetes that was inadequately controlled with diet and...

A 2-year trial compared tirzepatide with intensified conventional care in adults with early type 2 diabetes.

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.

In SOUL, oral semaglutide was associated with fewer composite heart failure events in patients with type 2 diabetes and baseline heart failure.

March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

A nationwide target trial emulation in US veterans with type 2 diabetes found that semaglutide initiation was associated with a twofold increased risk of nonarteritic anterior ischemic optic neuropathy...

An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...